PMID- 36929151
OWN - NLM
STAT- MEDLINE
DCOM- 20230512
LR  - 20230512
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 26
IP  - 5
DP  - 2023 May
TI  - Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: A pilot 
      prospective real-world study.
PG  - 878-884
LID - 10.1111/1756-185X.14663 [doi]
AB  - AIM: This study aimed to show the effectiveness of interleukin (IL)-23 inhibitors 
      in psoriatic arthritis (PsA) at weeks 12 and 24 in a real-world setting. 
      MATERIALS AND METHODS: Forty-three patients with active PsA were enrolled in this 
      study. These patients were treated with either guselkumab (n = 20) or 
      risankizumab (n = 23). Treatment responses at the 12th and 24th weeks were 
      evaluated with the parameters of the number of joints with active arthritis, 
      Psoriasis Area Severity Index (PASI) response rate, Bath Ankylosing Spondylitis 
      Disease Activity Index (BASDAI) score, Disease Activity Index for Psoriatic 
      Arthritis (DAPSA) score, and C-reactive protein (CRP) value. The study's primary 
      endpoint was BASDAI </= 4 and DAPSA </= 14 at week 24, and the secondary endpoint was 
      the absence of joints with clinically active arthritis signs at week 24. RESULTS: 
      IL-23 inhibition significantly improved all treatment response parameters at the 
      12th and 24th weeks (P < 0.001). While 90% of patients reached the primary 
      endpoint with anti-IL23 therapy, 74% achieved the secondary endpoint. Both 
      biologic-naive and biologic-experienced patients responded significantly to 
      anti-IL-23 therapy. Also, no adverse events related to anti-IL-23 agents were 
      observed. CONCLUSIONS: The response parameters indicating the severity of PsA 
      (the number of joints with active arthritis, BASDAI score, DAPSA score, and CRP 
      value) and a parameter indicating the severity of skin involvement, that is, PASI 
      score, significantly improved with anti-IL-23 therapy at weeks 12 and 24. 
      Moreover, significant improvement was achieved at week 24 compared to week 12 in 
      all response parameters.
CI  - (c) 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons 
      Australia, Ltd.
FAU - Ak, Tumay
AU  - Ak T
AUID- ORCID: 0000-0002-1548-7638
AD  - Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey.
FAU - Temiz, Sera Nur Yucesoy
AU  - Temiz SNY
AUID- ORCID: 0000-0001-9170-4262
AD  - Department of Dermatology, Cerrahpasa Medical Faculty, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey.
FAU - Taner, Meliksah
AU  - Taner M
AUID- ORCID: 0000-0002-3079-1881
AD  - Department of Dermatology, Cerrahpasa Medical Faculty, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey.
FAU - Ayla, Ali Yagiz
AU  - Ayla AY
AUID- ORCID: 0000-0003-2581-7992
AD  - Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical 
      Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
FAU - Aygun, Ahmet Atil
AU  - Aygun AA
AUID- ORCID: 0000-0003-0979-070X
AD  - Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey.
FAU - Engin, Burhan
AU  - Engin B
AUID- ORCID: 0000-0002-5140-1926
AD  - Department of Dermatology, Cerrahpasa Medical Faculty, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey.
FAU - Can, Gunay
AU  - Can G
AUID- ORCID: 0000-0001-5815-6700
AD  - Department of Public Health, Cerrahpasa Medical Faculty, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey.
FAU - Ugurlu, Serdal
AU  - Ugurlu S
AUID- ORCID: 0000-0002-9561-2282
AD  - Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical 
      Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20230316
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Biological Products)
RN  - 0 (Interleukin-23)
RN  - 089658A12D (guselkumab)
RN  - 90ZX3Q3FR7 (risankizumab)
SB  - IM
MH  - Humans
MH  - *Arthritis, Psoriatic/therapy
MH  - *Biological Products
MH  - Prospective Studies
MH  - Psoriasis/complications/therapy
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - *Interleukin-23/antagonists & inhibitors/immunology
OTO - NOTNLM
OT  - arthritis
OT  - guselkumab
OT  - interleukin-23
OT  - psoriasis
OT  - risankizumab
EDAT- 2023/03/18 06:00
MHDA- 2023/05/03 06:42
CRDT- 2023/03/17 09:50
PHST- 2023/02/24 00:00 [revised]
PHST- 2022/12/12 00:00 [received]
PHST- 2023/03/02 00:00 [accepted]
PHST- 2023/05/03 06:42 [medline]
PHST- 2023/03/18 06:00 [pubmed]
PHST- 2023/03/17 09:50 [entrez]
AID - 10.1111/1756-185X.14663 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2023 May;26(5):878-884. doi: 10.1111/1756-185X.14663. Epub 2023 
      Mar 16.